WO2002096420A3 - Method for treating nerve injury caused by surgery - Google Patents

Method for treating nerve injury caused by surgery Download PDF

Info

Publication number
WO2002096420A3
WO2002096420A3 PCT/US2002/016806 US0216806W WO02096420A3 WO 2002096420 A3 WO2002096420 A3 WO 2002096420A3 US 0216806 W US0216806 W US 0216806W WO 02096420 A3 WO02096420 A3 WO 02096420A3
Authority
WO
WIPO (PCT)
Prior art keywords
surgery
nerve injury
injury caused
treating
treating nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/016806
Other languages
French (fr)
Other versions
WO2002096420A2 (en
Inventor
Joseph P Steiner
Solomon Snyder
Arthur L Burnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Eisai Corp of North America
Original Assignee
Guilford Pharmaceuticals Inc
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals Inc, Johns Hopkins University filed Critical Guilford Pharmaceuticals Inc
Priority to EP02774120A priority Critical patent/EP1404325A2/en
Priority to JP2002592930A priority patent/JP2005500270A/en
Priority to MXPA03011095A priority patent/MXPA03011095A/en
Priority to CA002449019A priority patent/CA2449019A1/en
Publication of WO2002096420A2 publication Critical patent/WO2002096420A2/en
Publication of WO2002096420A3 publication Critical patent/WO2002096420A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The present invention relates generally to methods for treating or preventing nerve injury in a warm-blooded animal caused as a consequence of surgery by administering neurotrophic compounds described below. The invention relates more specifically to methods for treating or preventing nerve injury caused as a consequence of prostate surgery as well as erectile dysfunction.
PCT/US2002/016806 2001-05-29 2002-05-29 Method for treating nerve injury caused by surgery Ceased WO2002096420A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02774120A EP1404325A2 (en) 2001-05-29 2002-05-29 Method for treating nerve injury caused by surgery
JP2002592930A JP2005500270A (en) 2001-05-29 2002-05-29 Method for treating nerve injury that has occurred as a result of surgery
MXPA03011095A MXPA03011095A (en) 2001-05-29 2002-05-29 Method for treating nerve injury caused by surgery.
CA002449019A CA2449019A1 (en) 2001-05-29 2002-05-29 Method for treating nerve injury caused by surgery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29354401P 2001-05-29 2001-05-29
US60/293,544 2001-05-29

Publications (2)

Publication Number Publication Date
WO2002096420A2 WO2002096420A2 (en) 2002-12-05
WO2002096420A3 true WO2002096420A3 (en) 2003-02-06

Family

ID=23129511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016806 Ceased WO2002096420A2 (en) 2001-05-29 2002-05-29 Method for treating nerve injury caused by surgery

Country Status (6)

Country Link
US (1) US20030203890A1 (en)
EP (1) EP1404325A2 (en)
JP (1) JP2005500270A (en)
CA (1) CA2449019A1 (en)
MX (1) MXPA03011095A (en)
WO (1) WO2002096420A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6650943B1 (en) 2000-04-07 2003-11-18 Advanced Bionics Corporation Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
US6885895B1 (en) * 2001-04-26 2005-04-26 Advanced Bionics Corporation Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
US7203548B2 (en) * 2002-06-20 2007-04-10 Advanced Bionics Corporation Cavernous nerve stimulation via unidirectional propagation of action potentials
US20040015205A1 (en) * 2002-06-20 2004-01-22 Whitehurst Todd K. Implantable microstimulators with programmable multielectrode configuration and uses thereof
JP2008537684A (en) * 2005-01-24 2008-09-25 ニューロシステック コーポレイション Devices and methods for delivering therapeutic and / or other agents to the inner ear and other tissues
US7627383B2 (en) 2005-03-15 2009-12-01 Boston Scientific Neuromodulation Corporation Implantable stimulator
US20110077579A1 (en) * 2005-03-24 2011-03-31 Harrison William V Cochlear implant with localized fluid transport
US7801602B2 (en) * 2005-04-08 2010-09-21 Boston Scientific Neuromodulation Corporation Controlling stimulation parameters of implanted tissue stimulators
US7801600B1 (en) 2005-05-26 2010-09-21 Boston Scientific Neuromodulation Corporation Controlling charge flow in the electrical stimulation of tissue
US7729758B2 (en) 2005-11-30 2010-06-01 Boston Scientific Neuromodulation Corporation Magnetically coupled microstimulators
US8267905B2 (en) * 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US7803148B2 (en) 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
US8124636B2 (en) * 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
US10167259B2 (en) 2013-06-14 2019-01-01 The Board Of Regents Of The University Of Texas System Allosteric inhibitors of proteasome and methods of use thereof
US11020383B2 (en) 2017-04-20 2021-06-01 The Board Of Regents Of The University Of Texas System Methods for the treatment of cancer metastasis
WO2019152527A1 (en) 2018-01-30 2019-08-08 Board Of Regents, The University Of Texas System Pipecolic esters for inhibition of the proteasome

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330993A (en) * 1990-07-02 1994-07-19 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
WO2000032588A2 (en) * 1998-12-03 2000-06-08 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds
WO2001036388A1 (en) * 1999-11-12 2001-05-25 Gpi Nil Holdings, Inc. Aza compounds having neuronal activity
WO2001038304A1 (en) * 1999-11-22 2001-05-31 Gpi Nil Holdings, Inc. Heterocyclic ketone and thioester compounds and uses
WO2001046195A1 (en) * 1999-12-21 2001-06-28 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164547A (en) * 1988-07-07 1992-11-17 Texas Instruments Incorporated Articles having a dielectric layer on a metal substrate having improved adhesion
US5723459A (en) * 1991-05-09 1998-03-03 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US5620971A (en) * 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
US5726184A (en) * 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
DE69624921T2 (en) * 1995-06-09 2003-09-11 Novartis Ag, Basel rapamycin derivatives
EA003294B1 (en) * 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Metalloproteinase inhibitors, pharmaceutical compositions, their constituents, and their pharmaceutical use
US5717092A (en) * 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
ATE226573T1 (en) * 1996-08-28 2002-11-15 Procter & Gamble HETEROCYCLIC METALLOPROTEASE INHIBITORS
BR9712792A (en) * 1996-08-28 1999-12-14 Procter & Gamble Bidentate metalloprotease inhibitors.
CN1228771A (en) * 1996-08-28 1999-09-15 普罗克特和甘保尔公司 1,3-biheterocyclic metalloproteinase inhibitors
HUP0000505A3 (en) * 1996-08-28 2001-12-28 Procter & Gamble Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
US5846979A (en) * 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US6121280A (en) * 1998-03-24 2000-09-19 Pfizer Inc. Azabicyclic rotomase inhibitors
JP2002516857A (en) * 1998-06-02 2002-06-11 ブリストルーマイヤーズ スクイブ カンパニー Neurotrophic difluoroamide
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330993A (en) * 1990-07-02 1994-07-19 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
WO2000032588A2 (en) * 1998-12-03 2000-06-08 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds
WO2001036388A1 (en) * 1999-11-12 2001-05-25 Gpi Nil Holdings, Inc. Aza compounds having neuronal activity
WO2001038304A1 (en) * 1999-11-22 2001-05-31 Gpi Nil Holdings, Inc. Heterocyclic ketone and thioester compounds and uses
WO2001046195A1 (en) * 1999-12-21 2001-06-28 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors

Also Published As

Publication number Publication date
JP2005500270A (en) 2005-01-06
CA2449019A1 (en) 2002-12-05
EP1404325A2 (en) 2004-04-07
US20030203890A1 (en) 2003-10-30
WO2002096420A2 (en) 2002-12-05
MXPA03011095A (en) 2005-04-28

Similar Documents

Publication Publication Date Title
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
WO2003020212A3 (en) Treatment for central nervous system disorders
EP2567705A3 (en) Methods of treating cognitive dysfunction by modulating brain energy metabolism
WO2003050064A3 (en) Mitotic kinesin inhibitors
WO2003049678A3 (en) Mitotic kinesin inhibitors
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003049679A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2004009559A3 (en) Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
WO2004058148A3 (en) Mitotic kinesin inhibitors
DE60130799D1 (en) Synthese von 4-aminothalidomid enantiomeren
MY133667A (en) Quinazoline ditosylate salt compounds
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
WO2003096983A3 (en) Method of treating dyslipidemic disorders
ZA200106107B (en) Substituted porphyrins.
WO2003039460A3 (en) Mitotic kinesin inhibitors
AU2001263447A1 (en) Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2005060654A3 (en) Mitotic kinesin inhibitors
WO2004047673A3 (en) Treatment of liver disease with active vitamin d compounds
WO2005065183A3 (en) Mitotic kinesin inhibitors
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002592930

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002774120

Country of ref document: EP

Ref document number: 2449019

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/011095

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002308783

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002774120

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642